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Protection from hypoxemia-induced renal dysfunction by the thiophos-
phate WR-2721. The acute renal effects of hypoxemia-reoxygenation
and the putative protective action of WR-2721 [S-, 2-(3-aminopropyl-
amino)-, etylphosphosphorothioic acid], a drug with specific properties
such as PTH-secretion inhibiting, calcium lowering and free radical
scavenging activities, were investigated in anesthetized-ventilated rab-
bits. Glomerular filtration rate (GFR) and renal blood flow (RBF) were
assessed by the clearance of inulin and para-aminohippuric acid,
respectively. Each animal acted as its own control. Normoxemic
control rabbits showed no changes in renal hemodynamics and function
during 150 minutes. The administration of WR-2721 (75 mg/kg body wt
i.v.) to normoxernic animals induced a significant decrease in MBP,
RBF and diuresis, without affecting GFR. It significantly reduced
plasma levels of PTH, decreased calcemia and increased urinary
calcium excretion. In untreated hypoxemic-reoxygenated rabbits, 45
minutes of severe hypoxemia (P02 around 35 mm Hg) induced a
significant fall in MBP, GFR, RBF and diuresis, which persisted during
the 60-minute reoxygenation period. The administration of WR-272l
before hypoxemia or reoxygenation prevented the hypoxemia-induced
decrease in GFR and diuresis. Filtration fraction increased signifi-
cantly. The renal functional improvement observed in hypoxemic
rabbits administered WR-272l could be mediated by its effect on
calcium metabolism and/or its oxygen free radical scavenging proper-
ties.
In animal models as well as in humans, acute renal hypox-
emia and ischemia can lead to renal dysfunction. Previous
experiments in our laboratory have shown that acute hypox-
emia induces renal vasoconstriction in newborn and adult
rabbits, resulting in decreased glomerular filtration rate (GFR)
and renal blood flow (RBF) [1, 2]. The study of the pathophys-
iology and the prevention of the renal adverse effects of a
hypoxemic and/or ischemic injury has been the focus of major
research efforts in recent years [3—5]. Disturbances in calcium
uptake, activation of intrarenal adenosine as well as of other
vasoactive factors (endothelin, angiotensin II, ADH, catechol-
amines, etc.) have been shown to play key roles in the patho-
genesis of the renal response to hypoxia. Several pharmacolog-
ical agents such as methyixanthines [1], calcium entry blockers
[6, 7], atrial natriuretic peptide [8] or oxygen free radical
scavengers [9—11] are reported to be, at various degrees,
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effective in the protection from a hypoxemic/hypoxic stress in
animal models.
Recently, a new hypocalcemic agent, the WR-2721 [S-,
2-(3-aminopropylamino)-, etylphosphosphorothioic acid] has
been discovered [12]. WR-272l is an organic phosphorothioate
that provides selective protection to normal tissues against the
toxicity of radiation and alkylating agents in animals and
humans [13]. It seems to act as a free radical scavenger and/or
hydrogen donator and regulator of oxygen delivery and con-
sumption by tissues [141. Studies in animals and patients have
demonstrated that WR-272 1 can also inhibit parathyroid hor-
mone secretion (PTH) and additively inhibit the renal calcium
PTIT-independent reabsorption and the PTH-dependent bone
resorption [15, 16]. Recently, WR-2721 has been successfully
employed in experimental models of nephrocalcinosis [17] and
chronic renal failure with severe secondary hyperparathyroid-
ism [18]. Administration of this drug prevented both the neph-
rocalcinosis and the progressive deterioration of renal function.
Whether the properties of WR-2721 would be beneficial in a
model of acute renal hypoxic dysfunction has not yet been
tested.
The present study was performed 1) to study renal function
during acute normocapnic hypoxemia and subsequent reoxy-
genation in anesthetized mechanically-ventilated rabbits and 2),
to examine whether pretreatment with WR-2721 either imme-
diately before hypoxemia or before reoxygenation could pro-
vide protection against the hypoxemia-induced renal functional
changes. The overall results indicate that the hypoxemia-
induced fall in glomerular filtration rate can be prevented by the
intravenous administration of WR-2721.
Methods
Experiments were performed in 48 male adult New Zealand
White rabbits weighing 1.8 to 3.0 kg (mean sErf: 2.29 0.08
kg) and maintained on a normal diet. Food was withheld
approximately 20 hours before the study. Free access to water
was maintained.
Surgical procedure
Animals were initially anesthetized through the left marginal
ear vein with 30 mg/kg i.v. of Na pentobarbital. Supplemental
doses (10mg) were given as required to maintain a surgical level
of anesthesia. Mechanical ventilation (Harvard ventilator 661,
Harvard apparatus Co., Millis, Massachusetts, USA) with an
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02 enriched gas mixture (Fi02 about 0.30) was performed after
tracheal cannulation. A polyethylene catheter (PP 90) was
inserted into the femoral artery for arterial blood sampling and
continuous systemic blood pressure measurement (Hewlett-
Packard Pressure Recorder, 78205D, Palo Alto, California,
USA). A second catheter (PP 50) was similarly placed into the
right femoral vein for solute infusion and drug administration. A
total of about 800 IU of heparin was administered intrave-
nously. Both ureters were cannulated for urine collection. Body
temperature was continuously recorded rectally (Hewlett-Pack-
ard Temperature Recorder, 7823 1C) and maintained constant at
39°C using an infra-red lamp. After completion of the surgical
procedure, priming doses of inulin (125 mg) and para-aminohip-
puric acid (30 mg) were administered through the femoral vein.
Plasma levels were then maintained constant by infusing a
solution of Ringer containing inulin (2.5 mg%) and PAH (0.6
mg%) at the rate of 0.1 ml/min into the ear vein. A solution of
Ringer containing per liter 100 mmol NaCI, 5 mmol KCI, 50
mmol NaHCO3 and 50 g mannitol, was infused through the
femoral vein at the rate of 1 mllmin. Approximately 30 minutes
were spent for animal preparation and 60 to 90 minutes for
subsequent equilibration.
Experimental protocol
The following five experimental groups were studied.
Group A (N = 11, mean body wt 2.36 0.1 kg). Untreated
control rabbits were studied in normoxemic conditions for 150
minutes.
Group B (N 13, mean body wt 2.21 0.1 kg). Hypoxemic-
reoxygenated untreated rabbits, which following a normoxemic
control period of 30 minutes (P02 about 120 mm Hg) underwent
acute severe hypoxemia (P02 about 30 to 35 mm Hg) main-
tained for 45 minutes. Normoxemia was then restored and
maintained for 60 minutes.
Group C (N = 8, mean body wt 2.25 0.08 kg). Hypoxemic-
reoxygenated rabbits underwent the same protocol as group B
but were treated with WR-2721 (75 mg/kg body wt) as a bolus
slowly injected three minutes before hypoxemia.
Group D (N 8, mean body wt 2.34 0.07 kg). Hypoxemic-
reoxygenated rabbits underwent the same protocol as group B
but were treated with WR-272 1 (75 mg/kg body wt) as a bolus
slowly injected three minutes before reoxygenation.
Group E (N = 8, mean body wt 2.28 0.01 kg). Normoxemic
rabbits, after a 30-minute control period, received WR-2721 (75
mg/kg body wt) as a bolus and were subsequently studied over
120 minutes. In six animals of this group, arterial blood was
withdrawn during the control period, 60 and 120 minutes after
WR-272 1 for serum PTH determinations. The effect of WR-272 1
on the plasma renin activity (PRA) was measured in three
additional animals similarly treated. Blood sampling was ob-
tained 15 minutes before and 15, 30 and 60 minutes after
administering the drug, and was immediately chilled in ice.
After the control period in groups B, C and D, severe
hypoxemia was acutely induced and stabilized within 10 to 15
minutes by rapidly decreasing the fractional inspiratory oxygen
concentration (Fi02 around 0.10) to obtain the desired values of
P02. Normoxemia was later restored by rapidly increasing the
Fi02 to the normoxemic values (0.30).
For each experimental group, timed urine collection of 15
minutes each were obtained with blood sampling (1.2 ml)
between two consecutive urine samples. For groups B, C and D
the results of two control, three hypoxemic and four reoxygen-
ation urine samples were averaged to obtain a mean value for
the control (period I), hypoxemia (period II) and reoxygenation
experimental periods (period III), respectively.
Drug preparation
WR-272 1 was provided by the Drug Synthesis and Chemistry
Branch, Division of Cancer Treatment, National Cancer Insti-
tute, Bethesda, Maryland, USA. The drug was kept at 4°C and
freshly prepared before each injection; 75 mg/kg body wt (0.35
mmol/kg body wt) were dissolved in 5 ml of Ringer with the pH
adjusted to 7.22. The dose was slowly infused in the femoral
vein over three minutes after stopping the infusion of the Ringer
solution. This dose was chosen after preliminary experiments in
hypoxemic rabbits treated with 15, 45 or 75 mg/kg body wt of
WR-272l. The optimal beneficial effect on renal function,
without excessive decrease in mean blood pressure (MBP), was
observed after administering the latter dose.
Analytical methods
Arterial blood for pH, P02' P02, and hematocrit was col-
lected in anaerobically heparinized capillary tubes. Blood gas
determination was performed using a pH/blood gas analyzer
(Blood Gas System 278, Ciba-Corning Co, Medfield, Massachu-
setts, USA). Automatic anthrone and Bratton and Marshall
methods were used for the determination of inulin and PAH
concentrations (Autoanalyzer II, Technicon Instrument Corpo-
ration, Tarrytown, New York, USA). Plasma and urine total
calcium levels were measured by fluorometry (Calcium ana-
lyzer 940, Corning). Sodium and potassium were measured by
flame-photometry (Flame-Photometer 543, Instrument Labora-
tory, Lexington, Massachusetts, USA). Serum-intact immuno-
reactive PTH was determined using a two-site immunoradio-
metric assay (Allegro, Nichols Institute, San Juan Capistrano,
California, USA) [19], validated by Warren et al in the rabbit
[201. PRA was determined by a radioimmunological microassay
based on angiotensin I trapping by antibody [211.
Data analysis
The clearances of inulin (C1) and PAH (CPAH) were calcu-
lated according to standard formulae and used as indices of
GFR and RBF, respectively. Renal PAH extraction ratios
(EPAH) of 93.5 3.1%, 91.9% 5.4%, and 93.4 3.8% were
used for calculating RBF in the normoxemic, the hypoxemic
and the WR-272l-treated animals, according to values observed
in five additional normoxemic and hypoxemic rabbits and in
seven animals of group E. In the latter, renal venous blood was
withdrawn 15 minutes after administering 75 mg/kg body wt of
WR-2721. The EPAH values observed in the different groups did
not differ statistically (unpaired t-test).
Renal blood flow (RBF), filtration fraction (FF) and renal
vascular resistance (RVR) were derived from the following
equations:
RBF (ml/kg/min) = CPAH/[EpAH x (1 — Hct)}
FF (%) = (GFRJRPF) x 100
RVR (mm Hg/ml/kg/min) = MBP/RBF
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Table 1. Blood variables in cxperimental groups A-E
Group Period
Po2 Pc02 HCO3
mmol/liter pH
MBP
mm Hg
Ca
mmol/litermm Hg
A. Normoxemic
control rabbits
(N = 11)
I, mean
SEM
II, mean
SEM
III, mean
SEM
121.4
2.2
120.3
1.7
121.6
3.1
32.9
2.2
32.5
1.8
30.4
1.7
23.8
1.5
23.4
1.5
23.7
1.4
7.47
0.01
7.47
0.01
7.48
0.01
89.6
1.4
88.1
1.9
89.4
1.9
2.55
0.11
2,44b
0.12
2.39C
0.12
B. Hypoxemic
untreated rabbits
(N = 13)
I, mean
SEM
II, mean
SEM
III, mean
SEM
124.6
2.6
33•37C
1.1
l2O.9
2.2
30.0
1.2
32.1
1.2
301d
0.6
22.1
0.8
23.2
0.7
21.8"
0.7
7.48
0.01
7.47
0.01
7.47
0.01
89.0
2.0
76.0
2.4
737C
1.7
2.54
0.27
2.35
0.30
223b,d
0.30
C. Hypoxemic-
treated rabbits
(N = 8)
I, mean
SEM
II, mean
SEM
III, mean
SEM
117.7
2.7
35.1C
1.2
1l7.3
3.3
31.0
0.3
31.1
2.0
29.3
2.0
22.1
0.5
21.5
0.9
188a.d
0.7
7.46
0.01
745
0,02
744
0.03
89.6
3.9
759b
2.4
714b
2.9
2.43
0.21
1.94C
0.22
1.68
0.13
D. Reoxygenated-
treated rabbits
(N = 8)
I, mean
SEM
II, mean
SEM
III, mean
SEM
122.1
4.3
35.04C
0.9
l24.9
4.4
33.9
1.2
34.4
0.5
34.7
1.1
25.0
0.8
26.2
0.7
23.4e
1.2
7.48
0.01
7.49
0.01
744e
0.02
93.0
2.8
86.2
4.7
802b,d
3.5
2.48
0.92
2.39a
0.61
196c.f
0.52
E. Normoxemjc
treated rabbits
(N = 8)
I, mean
SEM
II, mean
SEM
III, mean
SEM
123.3
3.8
124.0
3.7
126.1
5.2
28.0
1.1
29.6
1.4
29.0
1.8
20.8
1.0
20.9
0.7
20.3
1.2
7.49
0.01
7.46
0.02
7.46
0.01
87.7
3.4
747C
2.7
76.7"
3.4
2.48
0.91
209b
0.43
0.03
1, control period (0—30 mm); ii, second experimental period (30—90 mm); III, third experimental period (90—150 mm).
P < 0.05, "P < 0.01 and C P < 0.001, levels of probability when comparing period Ito period II or III
d p < 0.05, e P < 0.01 and P < 0.001, levels of probability when comparing period II to period III
where MBP = mean blood pressure, RPF = renal plasma flow
=
Urinary calcium was related to GFR (jimollml GFR) by
dividing the amount of excreted calcium by the clearance of
inulin, as previously described [15].
All values are presented as mean SEM. Each animal was
used as its own control. The changes between control and
experimental periods have been evaluated by the paired Stu-
dent's i-test. In all cases a P <0.05 was considered statistically
significant.
Results
Blood parameters and kidney function variables observed in
the five groups are summarized in Table 1 and Table 2.
Group A
In this control group, MBP, ventilatory and acid-base param-
eters remained stable throughout the experiment. Renal func-
tion and the excretion of sodium and potassium did not vary,
while the urinary excretion and the plasma concentration of
calcium decreased slightly. A slight, significant (P < 0.001)
decrease in hematocrit (from 37.9 0.3 to 35.2 0.6%) and
plasma protein levels (from 53.1 1.0 to 47.8 1.0 g/liter) was
observed from the control period to the end of the experiment.
This decrease was present and similar in the five experimental
groups, and was a likely consequence of blood sampling and/or
slight extracellular expansion.
Group B
In response to acute normocapnic hypoxemia, MBP, urine
flow rate, GFR and RBF all decreased significantly (Fig. 1A).
These parameters remained depressed during 60 minutes of
reoxygenation (Fig. LB). The excretion of potassium was
slightly increased, while that of sodium and calcium was
decreased by the hypoxemia. No significant difference was
observed within the early reoxygenation period (first 30 mm)
and the late reoxygenation period (subsequent 30 mm, data not
shown).
Group C
The systemic administration of WR-272 1 immediately before
hypoxemia was associated with a significant improvement in
GFR and urine flow rate, as compared to the changes observed
in group B (Fig. IA). MBP and RBF were, however, still
severely depressed by the hypoxemia. As a result of opposite
changes in GFR and RBF, the filtration fraction rose signifi-
cantly. During reoxygenation, MBP and RBF remained im-
paired, urine flow rate decreasing below the levels observed
during the hypoxemia (Fig. 1B). GFR remained at its control
level, the filtration fraction remaining elevated. The changes in
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Table 2. Kidney function variables in experimental groups A-E
Group Period
V GFR RBF FF
%
RVR
mm Hg/mi/kg/mm
FENa
%
UKV
smol/kg/min
Uca/mi GFR
mol/ml GFRmi/kg/mm
A. Normoxemic I, mean 0.443 4.15 36.5 17.7 2.38 7.0 3.62 74.9
control rabbits SEM 0.05 0.19 1.3 0.7 0.07 1.1 0.30 18.6(N = 11) II, mean
SEM
III, mean
SEM
0.448
0.05
0.424
0.05
3.94
0.27
4.02
0.26
34.6
2.0
34.4
2.3
17.4
0.8
17.4
0.4
2.53
0.11
2.61
0.13
7.5
1.3
6.6
0.9
3.67
0.24
3,64
0.31
64.9
16.2
59.7
18.4
B. Hypoxemic I, mean 0.449 4.41 38.53 17.2 2.34 6.6 4.20 53.2
untreated SEM 0.03 0.27 2.0 0.7 0.20 0.8 0.30 10.5
rabbits H, mean 0.364a 3.60" 3041b 17.9 2.64 5.9 4.75 41.1
(N 13) SEM
III, mean
SEM
0.02
0.39
0.03
0.25
385b
0.30
1.8
318b
2,7
1.2
18.4
1.3
0.23
2.54
0.25
0.6
6.5
1.2
0.45
3.99"
0.32
11.8
35.8
7.9
C. Hypoxemic- I, mean 0.428 4.43 38.5 17.5 2.36 6.9 4.02 49.0
treated rabbits SEM 0.04 0.62 3.5 1.5 0.22 1.9 0.26 10.6(N = 8) II, mean
SEM
III, mean
SEM
0.412
0.04
0.317aI
0.03
4.48
0.59
4.04
0.51
313b
3.9
28.3"
2.3
20.9"
1.2
20.9"
1.4
2.52
0.22
2.52
0.13
5.3
1.2
41"
1.2
3.63
0.57
2.67a,d
0.40
131.7"
15.6
66.4
8.7
D. Reoxygenated- I, mean 0.415 4.38 38.1 17.2 2.4 6.3 3.25 51.0
treated rabbits SEM 0.03 0.30 2.4 0.4 0.11 0.7 0.26 14.8(N = 8) 11, mean
SEM
III, mean
SEM
0.336
0.03
0.432
0.04
362b
0.16
489a,f
0.29
29.13"
2.0
32.6a
2.0
18.7
0.7
224b.d
1.3
3.04
0.27
246d
0.17
5.6
1.0
4.7
0.7
4.19
0.44
3.90
0.29
40.7
11.4
2049b,
37.9
E. Normoxemic I, mean 0.408 4.64 36.3 19.4 2.34 6.1 3.83 31.5
treated rabbits SEM 0.06 0.49 1.2 1.9 0.10 1.9 0.41 12.4(N = 8) II, mean
SEM
III, mean
SEM
0.377
0.03
0.307"
0.03
4.99
0.57
474
0.47
34.1
3.5
306a.d
2.6
22.0"
1.5
227b
1.9
2.24
0.19
2.54
0.20
4.3
0.6
3.0
0.6
3.81
0.45
3.30
0.38
112.7a
35.7
83,6a
20.6
I, control period (0—30 mm); ii, second experimental period (30—90 mm); III, third experimental period (90—150 mm).
a P < 0.05, b p < 0.01 and "P < 0.001, levels of probability when comparing period Ito period II or III
"P < 0.05, P < 0.01 and P < 0.001, levels of probability when comparing period II to period III
calcium excretion associated with the administration of WR-
2721 at the onset of hypoxemia are illustrated in Figure 2A. The
increase in calcium excretion was noted immediately after
administering WR-2721, and vanished during reoxygenation.
The decrease in calcium plasma concentration was present in
both the hypoxemic and the reoxygenation periods (Fig. 2B).
Group D
The functional changes induced by hypoxemia were similar
to those observed in group B (Fig. 1A). Systemic administration
of WR-2721 immediately before reoxygenation was followed by
a significant improvement in GFR, which increased above the
normoxemic control level. This improvement occurred in spite
of a persistent decrease in MBP and RBF (Fig. 1B). The
filtration fraction rose sharply after the administration of WR-
2721, as did the excretion of calcium (Fig. 2A). The plasma
calcium concentration decreased significantly (Fig. 2B).
Group E
The administration of WR-2721 to normoxemic animals in-
duced a significant immediate decrease in MBP, persisting up to
the end of the experiment. Both urine flow rate and RBF
decreased one hour after the injection of WR-272 1, while GFR
remained unchanged throughout the experiment (Fig. 3A). The
filtration fraction rose significantly in the second hour following
the administration of WR-2721 (Fig. 3B). In response to WR-
2721, the excretion of calcium rose sharply and remained
elevated throughout the experiment, while the plasma calcium
concentration decreased progressively. Mean serum PTH lev-
els decreased from 7.2 0.8 pmol/liter during the control period
to 3.3 0.7 pmol/Iiter (P <0.001) and to 4.0 1.2 pmollliter (P
< 0.05) one and two hours after the injection of WR-272l,
respectively.
In the three additional animals where it was measured, PRA
increased significantly 30 minutes after injecting the WR-272 1
(from 1.23 0.03 ng/mllhr to 2.50 0.44 ng/mllhr) and was
slightly more elevated at 60 minutes (3.03 0.42 ng/mI/hr).
Discussion
The present results demonstrate that acute severe normocap-
nic hypoxemia (group B) is associated with a significant fall in
GFR in anesthetized rabbits. The drop in GFR occurred to-
gether with a concomitant decrease in RBF and MBP, and a
slight, albeit not significant, increase in RVR. These changes
were not reversible when the arterial oxygen tension was
restored. Failure of GFR or RBF to recover after reoxygenation
has also been observed in rats [22, 23] and dogs [24] undergoing
renal ischemia-reperfusion, or in rabbits undergoing hypoxic
hypoxia at P02 comparable to those obtained in our experiments
[25]. The mediators of the impairment in GFR and RBF present
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Fig. 1. A. Percent changes in MBP and renal function during hypox-
emia period. Symbols are: hypoxemic untreated rabbits (U), hypox-
ernie-treated rabbits () and reoxygenated-treated rabbits () *P <
0.05, 'P < 0.01 and ***< 0.001 when comparing with control period
levels. B. Percent changes in MBP and renal function during
reoxygenation.
during hypoxemia and subsequent reoxygenation are not yet
fully clarified. In previous experiments in our laboratory, we
demonstrated that the impairment in GFR and RBF induced in
rabbits by moderate hypoxemia (P02 -—40 mm Hg) of short
duration (20 mm) could be blunted by the administration of
calcium entry blockers [26, 271 or by antagonizing intrarenal
adenosine with low-dose theophylline [11. These observations
suggested that both calcium uptake and activation of endoge-
nous adenosine, an intermediate metabolite in the oxygen free
radical production, could play a role in the response to moder-
ate hypoxemia. To better define the role of these factors in the
renal response to hypoxia, we performed experiments where
the hypoxemic stress was more severe (P02 —35 mm Hg) and of
longer duration (45 mm), and administered an agent, WR-272l,
acting on both calcium and oxygen free radicals.
The administration of WR-2721 before hypoxemia (group C)
or before reoxygenation (group D) prevented or abolished the
decrease in GFR, without normalizing RBF. This beneficial
effect was associated with a marked increase in calcium excre-
tion, a decrease in sodium and potassium excretion, and an
immediate sharp decrease in plasma calcium concentration.
The mechanisms by which WR-2721 blunts the renal effects of
1.0 I I I
0 15 45 75 105
Time, minutes
Fig. 2. A. Urinary calcium excretion in hypoxemic untreated rabbits.
Symbols are: (—.—), hypoxernic-treated rabbits (—U—) and reoxygenated-
treated rabbits (—U—). *p < 0.05; ** < 0.01 and *** < 0.001 when
comparing with control period levels (—15 mm). B. Plasma calcium
concentration. < 0.05, < 0.01 and *P < 0.001 when
comparing with control period levels (0 mm).
the hypoxic stress are speculative. They could be related to the
specific action of this agent on calcium metabolism and/or to its
ability to act as an oxygen free radical scavenger. WR-2721 has
indeed been shown to produce a significant fall in the plasma
calcium concentration both in animals and in humans, reaching
its maximal effect two to six hours after administering the drug.
This effect has been ascribed to the direct inhibition of PTH
secretion [15]. In addition, animal experiments in thyroparathy-
roidectomized rats and in vitro studies have unveiled a minor
but significant PTH-independent hypocalcemic effect, which
can be explained by a decrease in renal tubular calcium reab-
sorption and by inhibition of bone resorption [15, 16]. The
decrease in PTH levels associated with WR-272 1 administration
in animals of group E suggests that both the hypocalcemia and
the increased calcium excretion were related, at least in part, to
PTH inhibition.
The effect of WR-272 1 on PTH and calcium metabolism could
thus mediate its protective action on the hypoxemic kidney.
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Fig. 3. A. Percent changes in MBP and renal function during the first
hour after WR-2721 injection. Symbols are: normoxemic untreated
rabbits (U) and normoxemjc treated rabbits (). *JJ < 0.05, < 0.01
and *** < 0.001 when comparing with control period levels. B.
Percent changes in MBP and renal function during the second hour after
WR-272l injection.
Disturbances of cellular calcium metabolism are known to be
key factors in the tissue response to an hypoxic stress. The
following evidence has been produced: 1) rats made hypercal-
cemic by vitamin D administration are more susceptible to
ischemia-induced renal failure [28]; 2) cellular calcium accumu-
lates in hypoxic kidney [29, 30]; 3) increased calcium concen-
tration in the infusate aggravates the hypoxic injury to the
isolated perfused kidneys 1311; 4) removing medium calcium
blunts the anoxic injury in cultured tubular cells [32], the
hypoxic injury to the medullary thick ascending limb of the
isolated perfused kidney [331 and the anoxic injury to isolated
proximal tubules [29]. Calcium channel blockers have also been
shown to ameliorate the ischemia-induced injury both in vivo
and in vitro [34], although it is not clear whether these agents
act primarily on vascular or renal tubular cells. In our experi-
ments of moderate hypoxemic renal dysfunction, the adminis-
tration of calcium entry blockers such as intravenous verapamil
or manganese chloride injected in the renal artery also dramat-
ically improved GFR [26, 27].
WR-2721 has been shown to present with oxygen free radical
scavenging properties, and has been successfully used in con-
ditions of radiation and alkalyting tissue damage, both in
clinical and experimental studies 112, 35, 36]. Because oxygen
free radicals have been claimed to be important mediators of
cell damage, including that produced by ischemia-reperfusion
[37], the oxygen free radical scavenging properties of WR-2721
could be attractive in this context. In a study in vitro, WR-2721
and WR-1065, the dephosphorylated active metabolite of WR-
2721, have been reported to be effective against cellular oxyda-
tive injury and associated calcium intracellular intrusion [38].
Moreover, a recent study in vivo has for the first time provided
evidence for the successful use of WR-1065 in improving
contractile function in the reperfused rat heart after prolonged
(60 mm) regional myocardial ischemia [39]. It should be pointed
out, however, that the putative role of reactive oxygen metab-
olites in the ischemic injury is still controversial [401. A role for
oxygen free radicals in the hypoxia-induced renal injury is also
far from established. Although renal adenosine, an intermediate
metabolite in the oxygen free radical's production, is increased
in the hypoxemic isolated rat kidney [41] neither the whole
rabbit kidney nor the isolated rabbit tubules appreciably metab-
olize purine nucleosides beyond hypoxanthine [42, 43]. The
suggestion that WR-2721 could exert its protective effect on the
hypoxemic kidney through its scavenging properties awaits
further clarification on the role of oxygen free radicals as
mediators of the hypoxemic renal injury.
Finally, WR-2721 could also influence renal function by
stimulating the activity of the renin-angiotensin system, as
shown in three normoxemic animals (group E). This effect may
be secondary to the WR-2721-induced hypocalcemia and/or to
the decrease in MBP associated with this agent. A decrease in
plasma calcium concentration similar to that produced by
WR-2721 has indeed been shown to increase renin-angiotensin
activity in dogs [44] and in the perfused rat kidney [45]. By
predominantly vasoconstricting the efferent arteriole [46], an-
giotensin II could favor glomerular filtration, accounting for
both the maintenance of GFR and the increase in filtration
fraction observed after WR-2721 injection in hypoxemic-reox-
ygenated rabbits (groups C and D).
The administration of WR-272 ito normoxemic rabbits (group
E) induced important hemodynamic and renal effects. The
significant decrease in MBP, persisting up to the end of the
two-hour observation period, has been reported in clinical and
experimental studies as an adverse effect of WR-2721 [47, 48].
Possible mechanisms for this decrease in blood pressure are
impaired cardiac output [48] and/or peripheral vasodilatation
[49]. This cardiovascular effect could explain the decrease in
RBF observed after WR-272l administration, when the actual
arterial pressure was at the lower limit of the autoregulatory
range of the rabbit [501. As mentioned above, the maintenance
of GFR in the presence of decreased MBP could be related to
increased intrarenal renin-angiotensin activity, and consequent
efferent vasoconstriction. The increased filtration fraction could
in turn explain the decrease in urine flow rate and sodium
excretion observed in the second hour after WR-272i, as a
consequence of an increase in the oncotic pressure in the
peritubular capillaries.
In conclusion, this study demonstrates a significant protec-
tive effect of WR-272i from the renal functional dysfunction
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induced by severe hypoxemia and persisting during the reoxy-
genation period. The relative contribution of the specific activ-
ities of WR-272 1 on calcium metabolism and on oxygen free
radicals remains to be assessed.
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